Overview
Glenmark Pharmaceuticals is a research-based pharmaceutical company that develops and markets branded and generic preparations. Its formulation activities include medical devices, OTC and prescription medicines, dermocosmetics and supplements, primarily across the United States, India, Europe and Latin America.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2026.
Results vs industry
News
Glenmark Poland awarded again with Best Quality HR Certificate 2023
Best Quality Employer program recognizes Glenmark Pharmaceuticals in 2019
Glenmark Pharmaceuticals honored with Best Quality HR Certificate 2020
Glenmark Pharmaceuticals twice awarded Solid Employer of the Year title
Glenmark Pharmaceuticals receives Gazele Biznesu 2015 title
Glenmark Pharmaceuticals awarded Solid Employer 2012 title
Industry
Bank accounts
Registered as a VAT taxpayer on 2008-06-20. Active
76 1600 1462 1744 1083 6000 0001
11 1030 1508 0000 0008 0480 1014- 22 1600 1462 1744 1083 6000 0003
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Aug 26, 2016 | Merger plan |
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, the company is represented by two members of the management board acting jointly.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Glenmark Holding Sa | 10,000 | $1,350,621.29 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Orkla CareS.A. | $43,777,691.06 | orklacare.com.pl | ||
| Synkmedsp. z o.o. | $20,634,200.47 | synkmed.pl | ||
| Intimexsp. z o.o. + limited partnership | $18,994,512.90 | intimex.com.pl | ||
| Medif sp. z o.o.sp. k. | $13,126,958.83 | medif.com | ||
| PromedS.A. | $12,643,674.56 | promed.com.pl | ||
| AO East Europesp. z o.o. | $12,156,227.53 | aoeasteurope.pl | ||
| MassmedicaS.A. | $8,216,274.00 | massmedica.com | ||
| SPA Landsp. z o.o. | $4,782,973.66 | hydrafacial.pl | ||
| Hair Partnerssp. z o.o. | $4,347,484.74 | hairpartners.pl | ||
| Balmed Polandsp. z o.o. | $3,140,735.80 | balmed.it |
Change history
| Date | Event | |
|---|---|---|
| 2023-09-26 | Address change (Osmańska 14, 02-823, Warszawa → Ul. Józefa Piusa Dziekońskiego 3, 00-728, Warszawa) | |
| 2018-03-29 | Share capital change (4,050,000.00 PLN → 5,000,000.00 PLN) | |
| 2016-11-02 | Share capital change (1,850,000.00 PLN → 4,050,000.00 PLN) | |
| 2016-11-02 | Name change (Glenmark Distributors → Glenmark Pharmaceuticals) | |
| 2015-02-27 | PKD change (Removed: 10.4, 10.5, 10.6, 10.8, 20.1, 20.30.Z, 20.4, 20.5, 20.60.Z, 41.10.Z, 41.20.Z, 46.12.Z, 46.17.Z, 46.18.Z, 46.19.Z, 46.33.Z, 46.49.Z, 47.29.Z, 47.73.Z, 47.74.Z, 47.75.Z, 47.91.Z, 49.41.Z, 64.19.Z, 64.30.Z, 64.91.Z, 64.99.Z, 66.30.Z, 68.10.Z, 68.20.Z, 70.10.Z, 70.21.Z, 70.22.Z, 71.20.A, 71.20.B, 72.11.Z, 72.19.Z, 73.20.Z, 74.90.Z, 77.40.Z, 82.30.Z) |
FAQ
Last updated: 2026-10-07